Danwen Zheng

Danwen Zheng


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 November 2025 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
HWHaiyan Wang
Haiyan Wang
ZSZhi-Chao Sun
Zhi-Chao Sun
CDChunlei Dai
Chunlei Dai
RLRan Liao
Ran Liao
RLRan Lin
Ran Lin
YLYuntao Liu
Yuntao Liu
Acute respiratory distress syndrome (ARDS) is a life-threatening disease. In the clinical management of ARDS, current treatments such as glucocorticoids and protease inhibitors encounter significant challenges due to their high toxicity, limited administration routes, or poor targeting. These limitations highlight the urgent need for innovative therapeutic strategies. Songorine (Son), a compound derived from the herb Aconitum carmichaelii Debeaux, possesses good antioxidant and anti-inflammatory properties, exhibiting great potential for treating ARDS. However, its clinical application is partially constrained by low aqueous solubility and uncertain efficacy for ARDS. In this study, we developed a lung-targeted lipid nanomedicine by encapsulating Son in dipalmitoyl phosphatidylcholine (DPPC) liposomes (Son@liposome, Son-lipo). In a lipopolysaccharide-induced ARDS mouse model, we demonstrated that Son-lipo effectively targeted inflamed lung tissues with commendable biocompatibility. Further, Son-lipo significantly alleviated multiple ARDS phenotypes such as endothelial barrier damage, lung edema, pulmonary dysfunction, and alveolar lesion, which involved uncontrolled inflammation, oxidative stress, and cell apoptosis. RNA sequencing and Western blotting analyses revealed that Son-lipo inhibited the activation of the TLR4/NF-κB/NLRP3 pathway responsible for ARDS. In conclusion, our study successfully developed an inhalable lipid-nanomedicine (Son-lipo) as a novel therapeutic strategy for ARDS. It elucidates the formulation's ability to mitigate ARDS by repairing the endothelial barrier and reversing the inflammatory microenvironment, thereby providing a promising candidate drug for improving clinical management of ARDS.

2 January 2026 in Medicine
Verified
Journal Article
Open access
LTLijuan Tang
Lijuan Tang
ZJZichen Jie
Zichen Jie
DZDanwen Zheng
Danwen Zheng
QHQiaoli Hua
Qiaoli Hua
SCShubin Cai
Shubin Cai
ZZZhongde Zhang
Zhongde Zhang
Post-infectious symptoms of COVID-19—such as persistent dyspnea, psychological disturbances, and reduced quality of life—continue to pose significant health challenges for convalescent patients. Traditional Chinese Medicine (TCM) has been widely used as a complementary therapeutic approach to alleviate post-COVID sequelae. This retrospective study evaluated the clinical effects of 2 TCM prescriptions, Fuzheng Yifei Formula (FZYF) and Fuzheng Anshen Formula (FZAS), on the psychological state, dyspnea, and quality of life among patients recovering from COVID-19. Medical records of 114 COVID-19 convalescent patients treated at the Second Affiliated Hospital of Guangzhou University of Chinese Medicine were retrospectively reviewed. Based on the treatment regimen, patients were categorized into 2 groups: FZYF (n = 77) and FZAS (n = 37). Clinical data were collected at baseline, 7 days, 14 days, and during follow-up. Changes in psychological status, dyspnea severity, and quality-of-life scores were analyzed using validated assessment tools, including the General Health Questionnaire (GHQ-12), the Modified Borg Scale, and the 36-Item Short Form Survey (SF-36) Health Survey. Both FZYF and FZAS were associated with significant improvements in psychological well-being, with mean GHQ-12 scores decreasing from 14.5 at baseline to 9 at follow-up ( P < .05). Dyspnea symptoms improved across both groups, with an average reduction of 3.5 points on the Modified Borg Scale. The SF-36 results indicated notable enhancements in both physical and mental health domains, showing mean improvements of 22% and 23%, respectively. No statistically significant difference was found between the 2 formulas, although FZYF showed slightly superior benefits in respiratory symptom relief. The retrospective analysis suggests that the FZYF may help alleviate long-term respiratory and psychological symptoms among COVID-19 convalescents, thereby potentially improving their overall quality of life. The FZAS, while showing comparable trends of benefit, appeared to exert relatively greater influence on mental and emotional well-being. However, these findings should be interpreted with caution given the non-randomized design and limited sample size, and further validation through large-scale controlled studies is warranted.